Novartis heart drug's trial failure cast doubt on Amgen and Lilly's cholesterol race

发生了什么

Pelacarsen lowered Lp(a) levels in more than 8,000 patients but did not reduce the risk of heart attacks, strokes, or cardiovascular death

摘要按规则整理自下方来源原文

来源